Loading data for ENVB — first visit, this takes a few seconds.
Enveric Biosciences, Inc. (ENVB): ціна акції, аналіз і дані
Внутрішня вартість
Прогноз аналітиків
Прогнози по акціях →Останні результати
| Факт | До прогнозу | Зміна р/р | |
|---|---|---|---|
| Виручка | $0 | n/a | n/a |
| EPS | -$2,03 | +$0,73 | +98.94% |
Показники
- Купівля
- 1.08
- Ринкова капіталізація
- 6.62M
- Виручка (ttm)
- n/a
- Чистий прибуток (ttm)
- -12.1M
- 1.11
- -12.18
- n/a
- -1.05
- P/B (ttm)
- 0.72
- P/S (ttm)
- n/a
- Дата звіту
- n/a
- Продаж
- 1.81
- Обсяг торгів
- 104,183
- Сер. обсяг (20 дн.)
- 120,341
- Відкриття
- 1.48
- Попереднє закриття
- 1.44
- Діапазон дня
- 1.41 - 1.54
- Діапазон за 52 тижні
- 1.17 - 13.25
- Аналітик
- n/a
- Цільова ціна
- n/a
- Дивіденди
- n/a
- Екс-дивідендна дата
- Apr 23, 2008
Про Enveric Biosciences, Inc.
Профіль →Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.